Urinary Bladder Neoplasms: all 1,649 studies

Page 16 of 17. Open to participants first (427), then studies with results posted, then the rest; newest registration first within each.

• USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node MetastasesCompletedNCT00622973Phase 3
• Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and StagingCompletedNCT00612326
• Pilot Studie of Lipiodol Demarcation of the Tumour in Bladder CancerCompletedNCT00609843Not applicable
• Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder CancerCompletedNCT00582387
• Germline Alterations of Tumor Susceptibility Genes in New York Cancer PatientsActive, not recruitingNCT00579514Not applicable
• SU011248 for Platinum-Refractory Urothelial Cancer Evaluation TrialCompletedNCT00578526Phase 2
• Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial TumorsActive, not recruitingNCT00567684Not applicable
• Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder CancerCompletedNCT00556621Phase 1/2
• Effect of Dietary, Lifestyle, and Environmental Factors on Patients With Early-Stage Bladder CancerStatus unknownNCT00553566
• Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder CancerStatus unknownNCT00553345Phase 3
• Quality of Life in Patients With Bladder CancerStatus unknownNCT00553215
• Different Factors Affecting Patients With Newly Diagnosed Bladder CancerStatus unknownNCT00553124Phase 3
• Sorafenib and Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative IntentCompletedNCT00544609Phase 1
• Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary BladderCompletedNCT00539773Not applicable
• A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816)CompletedNCT00536588Phase 1
• Gene Expression Profiling in Patients With Invasive Bladder Cancer Receiving Methotrexate, Vinblastine, Doxorubicin, and CisplatinTerminatedNCT00516750Phase 2
• Changes in Prostate Specific Antigen Levels During Synergo Therapy-Intravesical Chemotherapy Instillations Combined With HyperthermiaStatus unknownNCT00491296
• Intravesical Chemotherapy Treatment of Superficial Bladder CancerCompletedNCT00491114Phase 2
• Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder CancerCompletedNCT00490880Phase 2
• Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid TumorsCompletedNCT00479128Phase 1
• OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid TumorsCompletedNCT00471432Phase 1
• Cone Beam CT Scanning in Lung and Bladder Cancer.CompletedNCT00469066
• Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder CancerCompletedNCT00406068Phase 2/3
• Safety and Proof of Concept Study of Intravesical DTA-H19 in Patients With Superficial Bladder CancerCompletedNCT00393809Phase 1/2
• First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based TherapyCompletedNCT00389155Phase 2/3
• Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder CancerTerminatedNCT00384891Phase 3
• Zinc Supplements in Lowering Cadmium Levels in SmokersCompletedNCT00376987Phase 2
• BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder CancerTerminatedNCT00352079Phase 3
• Bladder Cancer Chemoradiation Using Intensity Modulated Radiation TherapyTerminatedNCT00350688Not applicable
• Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of BladderCompletedNCT00343356Phase 2
• The New England Bladder Cancer StudyCompletedNCT00342875
• Interdisciplinary Case-Control Study of Bladder Cancer in SpainCompletedNCT00341861
• Calibration of Urine pH Strips for NCI Case-Control Studies on Bladder Cancer and Comparison of DNA Yields From Buccal Cells Collected Through Two Different MethodsCompletedNCT00339443
• Exercise in Improving Mobility and Reducing Fatigue and/or Weakness in Older Cancer SurvivorsCompletedNCT00335491Not applicable
• Combined Use of BCG and Interferon Alpha in Bladder CancerCompletedNCT00330707Phase 2/3
• Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer.CompletedNCT00330499Phase 3
• Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder CancerCompletedNCT00322699Phase 1/2
• NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.CompletedNCT00318266
• Survivin Urine mRNA Assay Risk of Bladder Cancer StudyCompletedNCT00315653
• Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial TractCompletedNCT00315237Phase 3
• Lapatinib and Paclitaxel in Treating Patients With Advanced Solid TumorsCompletedNCT00313599Phase 1
• Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During PregnancyCompletedNCT00310115
• Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the UrotheliumCompletedNCT00310011Phase 2
• Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral ResectionCompletedNCT00303654Not applicable
• A Study of MLN8054 in Patients With Advanced Solid TumorsTerminatedNCT00249301Phase 1
• Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCTCompletedNCT00246974Phase 2
• Identifying Methylation Biomarkers for Monitoring Bladder TumorsStatus unknownNCT00244205
• Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial CancerTerminatedNCT00237575Phase 3
• Antiangiogenic Effects of BCG on Urinary Concentration of Angiogenic FactorsTerminatedNCT00216814
• URO-BCG-4 : Bladder Tumors ImmunotherapyCompletedNCT00213655
• A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder CancerCompletedNCT00192049Phase 2
• Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.CompletedNCT00191711Phase 2
• Combidex USPIO - Ultra-small Superparamagnetic Iron OxideCompletedNCT00188695Phase 1/2
• Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder CancerCompletedNCT00186277Phase 2
• Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder CancerStatus unknownNCT00146276Phase 3
• Phase II Trial of EOquin in High-risk Superficial Bladder CancerCompletedNCT00141531Phase 2
• Paclitaxel, Carboplatin and Gemcitabine in the Treatment of Patients With Advanced Transitional Cell Cancer of the BladderCompletedNCT00136175Phase 2
• Cost-Effectiveness in Bladder CancerStatus unknownNCT00126958
• Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) FailureStatus unknownNCT00109655Phase 1
• Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the UrotheliumCompletedNCT00101608Phase 2
• Microsatellite Analysis of Urinary Sediment in Detecting Bladder CancerCompletedNCT00095589
• Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder CancerCompletedNCT00088946Phase 2
• S0400, FR901228 in Treating Patients With Advanced Cancer of the UrotheliumTerminatedNCT00087295Phase 2
• Celecoxib and Rosiglitazone in Treating Patients Who Are Undergoing Cystoscopic Surveillance for Early-Stage Noninvasive Carcinoma of the Bladder or Radical Cystectomy for Muscle-Invasive Carcinoma of the BladderWithdrawnNCT00084578Not applicable
• Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the UrotheliumCompletedNCT00082719Phase 1
• Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal RemnantActive, not recruitingNCT00082706Phase 2
• Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the UrotheliumCompletedNCT00080795Phase 2
• TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the UrotheliumCompletedNCT00077688Phase 2
• Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell CarcinomaCompletedNCT00072150Phase 2
• Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing CystectomyTerminatedNCT00072137Phase 1
• S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With ChemotherapyCompletedNCT00066612Phase 2
• Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or UreterCompletedNCT00066352Phase 2
• S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the UrotheliumCompletedNCT00055835Phase 2
• Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder CancerStatus unknownNCT00054626Phase 3
• Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the UrotheliumCompletedNCT00053209Phase 2
• Cystoscopy and Hexyl 5-Aminolevulinate in Detecting Carcinoma In Situ in Patients With Bladder CancerCompletedNCT00052637Phase 3
• Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory MalignanciesTerminatedNCT00050687Phase 1/2
• Tipifarnib in Treating Patients With Recurrent Bladder CancerCompletedNCT00047216Phase 2
• Chemotherapy With or Without Surgery in Treating Patients With Bladder CancerTerminatedNCT00042887Phase 3
• Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder CancerCompletedNCT00033436Phase 3
• Decitabine in Treating Patients With Advanced Solid TumorsCompletedNCT00030615Phase 1
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionCompletedNCT00030498Phase 1
• Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract CancerCompletedNCT00028860Phase 2
• Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder UrotheliumCompletedNCT00028756Phase 3
• Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder CancerCompletedNCT00024349Phase 3
• BCG With or Without Mitomycin in Treating Patients With Bladder CancerCompletedNCT00023842Phase 2
• Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract CancerCompletedNCT00022191Phase 3
• Ixabepilone in Treating Patients With Advanced Urinary Tract CancerCompletedNCT00021099Phase 2
• LMB-9 Immunotoxin in Treating Patients With Advanced Solid TumorsCompletedNCT00019435Phase 1
• Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous TreatmentCompletedNCT00016237Phase 1
• Combination Chemotherapy in Treating Patients With Bladder CancerCompletedNCT00014534Phase 3
• Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid TumorsCompletedNCT00014456Phase 1
• Gemcitabine in Treating Patients With Recurrent or Refractory Bladder CancerWithdrawnNCT00014287Phase 1
• Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the UrotheliumCompletedNCT00014274Phase 2/3
• S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary TractCompletedNCT00014144Phase 2
• Bladder Cancer Case Control Study of Arsenic in WaterCompletedNCT00011518
• Arsenic Trioxide in Treating Patients With Urothelial CancerCompletedNCT00009867Phase 2
• Suramin in Treating Patients With Recurrent Bladder CancerCompletedNCT00006476Phase 1
• R115777 in Treating Patients With Advanced Bladder CancerCompletedNCT00006376Phase 2
• SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary TractCompletedNCT00006351Phase 2

← Urinary Bladder Neoplasms overview